X hits on this document

15 views

0 shares

0 downloads

0 comments

5 / 6

he tumor

fulfilled all

rebellar

hemangioblastoma.

igiomas

excludes the

ippel-Lindau

syndrome.

possibility It light-microscopic The is absence of the intriguing,

criteria of complete

for a retinal von

however,

patient’s early father age in died at a cardio- could Lat the latively and what brothers described polycythemia hemangioblastoma had two were as scular Indeed, advanced events. irry a risk of such ay be an inherited events. trait Because ( 7 5 ) , f u r t h e of investigations r

e family

are

warranted.

In conclusion,

rum

erythropoietin

rthemia.

Previous

this

determination

in evaluating

poly-

experience

with

competitive

radio-

case demonstrates

the

utility

of

indicates limita- from improve- immuno- likely determina- and in de- that such assays have of primary However, smunoassays ons with condary ants etric Lcrease to the resolution polycythemia. radioimmunoassays as the one we regard absolute in competitive and are such used to assays of serum erythropoietin the value in evaluating and monitoring hematological tumors. disorders ons cting

?ferences Lehmann

J. Hypo-prothrombinemia

produced

by 3,3’-methyl-

Le-bis(4-hydroxycoumann).

Lehmann rculosis.

J. Para-aminosalicylic

Lancet

1946;i:15-7.

Science

1942;96:345-6. acid in the treatment

of tu-

Ryan ove, International SH), Panel UK F. Tuberculosis: Swift, 1992:446 Committee on Diagnostic the greatest story pp. for Standardization Applications

never told. Broms-

in Haematology of Radloisotopes

in

aematologr. d plasma

Standard volume.

techniques Br J Haematol

for measurement 1973;25:801-14.

of red-cell

BerkPD,

GoldbergjD,

Donovan

PB, Fruchtman

SM, Berlin

NI,

asserman ra based emathi

LR. Therapeutic on Polycythemia 1986;23:132-43.

recommendations Vera Study

Group

in polycythemia

protocols.

Semin

Revesz

easurement

P,

Carneskog of spleen

J, size

Wadenvik

H, Jarneborn

using gamma

camera

L, Kutti scintigraphy

J. in

sential

thrombocythaemia.

Eur

J Haematol

1993;51:141-3.

Andre

M, Ferster

A, Toppet

M, Fondu

P, Dratwa

M, Bergmann

Performance id results

for

of an immunoradiometric

specimens

from

anemic

and

assay

of erythropoietin

polycythemic

patients.

Lin Chem Nanus

1992;38:758-63. DM, Schmitz-Drager

RJ,

Lee

AC, Vianus

V, Cordon-

C, Albino

AP,

Reuter YE.

factor

in primary

human

rdo

Expression

owth

renal tumors:

of basic

flbroblast

correlation

with

or survival.

Erslev

AJ,

J Nati Caro

Cancer J. Pure

Inst

1993;85:1597-9.

erythrocytosis

classified

according

to

J Med

1984;76:57-61.

AS,

Richman P,

Sadowit

z

ythropoietin

titers. Am

I. Souid

AK,

Dubansky

PD. Polycy-

emia:

a review

article

yto

Wilms’ Horton

tumor. JC, Harsh

and Pediatr GR,

case report Hematol

Fisher

JW,

of erythrocytosis

Oncol

1993;10:215-21.

Hoyt

WF. Von

second-

Hippel-

ndau ietin

disease in cyst

and fluid

erythrocytosis:

from

a

brainstem

radioimmunoassay hemangioblastoma.

of erythro- Neurol-

y 1991;41:753-4.

Wellstein

A.

Why

monitor

me? [Editorial].

J Natl

Cancer

angiogenic

factors

Inst

1993;85:1597-9.

in

patients’

L Fujimoto

K, Ichimori

Y, Kakizoe

T, Okajima

E, Sakamoto

H,

igimura

T,

Terada

M. Increased

serum

owth

factor

in

patients

with

renal

ophys

Res

Commun

Barosi

G. Control

199 1;180:386-92.

of erythropoietin

levels

cell

of basic carcinoma.

fibroblast Biochem

production

in man

[Re-

ew]. Haematologica

1993;78:77-9.

i. Zon

LI. The history

ythropoietin

in clinical

of erythropoietin. applications.

An

In: Garrnck international

MB, ed. perspec-

Marcel

Dekker,

Iland

H, Rosenthal

re. New York:

Murphy

5,

1990:1-38.

D, Laszlo

J. Essential

throm-

bocythemia:

an interim

Group.

Semin

Hematol

report

from the Polycythemia

1986;23:177-82.

Vera Study

17. Rutherford C, Goldberg

binant

human

CJ, Schneider

MA.

Efficacy

of

erythropoietin

H, Kim DH,

Brugnara

regimens

for recom-

perisurgical

setting

TJ, Dempsey

different

dosing

in

a simulated

the Med 18. HM,

importance

of

1994;96:139-45. Anastassiades

Hyde K, et

iron

availability

in optimizing

response.

Am J

D, Howarth

J, Shanks

of iron

requirements

EG, Howarth

D, Waters

al. Monitoring

in renal

patients 53.

on erythropoietin.

Nephrol

Dial Transplant

1993;8:846-

19.

Westwood

N, Dudley

JM,

Sawyer

B, Messinez

M,

Pearson

TC.

Primary criteria. 20. Cotes

polycythaemia:

Eur

J PM,

Haematol Dor#{233CJ,

diagnosis by 1993;51:228-32.

Yin

JAL,

non-conventional

Lewis SM,

positive

Messinezy M,

Pearson TC, erythropoietin 1986;315:283-7.

Reid C. Determination in the investigation

of serum of erythrocytosis.

immunoreactive N Engl J Med

21. Wide erythropoietin 22. BirgegArd polycythaemia 1992;81:603-6. L,

Bengtsson in human

C, serum. Birgegrd Br J Haematol G. Circadian 1989;72:85-90. rhythm

G, Wide L. Serum

erythropoietin

and

after

phlebotomy

treatment.

in the diagnosis Br J Haemathl

of

of

biology and biochemistry of eryth- applica- Dekker, 23. Fritsch ropoietin. tions. An 1990:39-58. 24. Krantz 25. Goldberg erythropoietin EF. The In: Garnick international molecular MB, ad. Erythropoietin in clinical Marcel perspective. New York: SB. Erythropoietin MA, Dunning gene: evidenc [Review]. SF, Bunn that the Blood HF. oxygen 1991;77:419-34. Regulation sensor the is a heme of e

protein.

Science

1988;242:1412-5.

26.

Koury

ST,

Semenza

GL. Localization

of erythropoietin-produc.

ing cells

in the livers

and kidneys

of transgenic

mice.

In: Bauer

C,

Koch KM, physiology

Seigalla and

P, Wieczorek

L,

clinical

applications.

ads.

Erythropoietin. New York: Marcel

Molecular Dekker,

1993:55-66. 27. Maxwell

AP,

Lappin

TRJ,

Johnston

CF,

Bridges

JM,

Mc-

Geown

MG. Erythropoietin

gene expression

in kidney

tissue

by

in

situ 28.

hybridization. Semenza

GL

.

pression

in transgenic

C, Koch

KM, Scigalla

Br J Haematol

Regulation

of

1990;74:535-9. human erythropoietin

mice and human

P, Wieczorek

L,

ads. hepatoma cells. Erythropoietin.

gene ex- In: Bauer Molec-

ular

physiology

and clinical

applications.

New York:

Marcel Dek-

ker,

1993:21-9.

29.

Wang GL,

Semenza

GL. General

involvement

of hypoxia-

Proc

Natl

Egrie

JC, gene.

30. Lin FK,

Suggs

5, Lin CH,

Browne

JK,

Smalling R,

et al. Cloning

and

expression

of the

human

erythropoietin

31. Jacobs K,

Shoemaker

Mufson

A, et

al. Isolation

to hypoxia.

RJ, and

response

SD, Kaufman of genomic

inducible Acad Sci

Proc Soc Natl

and

characterization

factor USA

1 in transcriptional 1993;90:4304-8.

Acad Sci USA

1985;82:7580-4.

C, RudersdorfR,

Neil

cDNA clones

of human

32. Law ML,

Cal G-Y,

EPO. Nature Lin F-K, Wei

Q,

1985;313:806-10.

Huang

S-Z,

Hartz

JH,

et al.

Chromosomal

assignment

its DNA

polymorphism.

of the human Proc Natl Aced

erythropoietin

gene

Sci USA

1986;83:6920-4.

and

33.

Watkins

PC, Eddy

R, Hoffman

Gall

J, et al. Regional

human

chromosome

assignment

region

7pter

*

N, Stanislovitis

P, Beck AK,

of the

erythropoietin

gene to

q22.

Cytogenet

Cell Genet

1986;42:214-8.

34. Wide L , human serum

35. Fisher JW. duction. Annu

Bengtsson

C. Molecular

charge

heterogeneity

erythropoietin. Pharmacologic Rev Pharmacol

Br J Haematol modulation

1990;76:121-7. of erythropoietin

Toxicol

1988;28:101-22.

of

pro-

M, Rondon

I, Beckman

Fisher JW.

Increased

renal carcinoma

cells

36. Ueno

in

Cole human

FE,

B, Brookins

secretion

of

response

to

J, Nakashima

erythropoietin atrial natriuretic

J, in

factor.

Am

J Physiol

1990;259:C427-31.

37.

Hoeldtke

RD, Streeten

DHP.

Treatment

of orthostatic

hypo-

tension

with

erythropoietin.

N Engl

J Med

1993;329:611-5.

Eckardt

K-U, Clemons

G, Froesch

ER, Bauer

factor

I stimulates

erythropoiesis

in hy.

1988;85:7825-9.

Sci USA

Aced

38. Kurtz

A, ZapfJ,

Proc Natl

growth

rats.

pophysectomized

C.

Insulin-like

Aron BioFactors 39.

40.

Scholz

DC. Insulin-like 1992;3:211-6.

growth

H, Baler

W, Ratdliffe

P,

factor

I

and

Eckardt

K,

erythropoiesis.

Zapf

J,

Kurtz

A,

CLINICAL

CHEMISTRY,

Vol. 40, No. 11, 1994

2097

Document info
Document views15
Page views15
Page last viewedFri Dec 09 22:15:29 UTC 2016
Pages6
Paragraphs2143
Words5152

Comments